1190-53-0 Usage
Description
Buformin Hydrochloride, a biguanide derivative, is a white solid with antihyperglycemic activity. It works by delaying glucose absorption from the gastrointestinal tract, increasing insulin sensitivity and glucose utilization in peripheral cells, and inhibiting hepatic gluconeogenesis. Additionally, it deactivates the glycolytic pathway by suppressing glyceraldehyde 3-phosphate dehydrogenase gene expression, which can lead to lactic acidosis. Buformin also inhibits the mitochondrial respiratory complex I and the mitochondrial ATP synthase, and has been examined for antitumor activity due to its ability to disrupt the unfolded protein response transcription program during glucose deprivation, inducing cell death in glucose-deprived tumor cells.
Uses
Used in Diabetes Management:
Buformin Hydrochloride is used as an antihyperglycemic agent for improving insulin resistance in patients with diabetes mellitus. It helps in managing blood sugar levels by delaying glucose absorption, increasing insulin sensitivity, and inhibiting hepatic gluconeogenesis.
Used in Pharmaceutical Industry:
Buformin Hydrochloride is used as an active pharmaceutical ingredient in the development of drugs for the treatment of diabetes mellitus. Its ability to improve insulin resistance and manage blood sugar levels makes it a valuable component in pharmaceutical formulations.
Used in Cancer Research:
Buformin Hydrochloride is used as a potential antitumor agent in cancer research. Its ability to disrupt the unfolded protein response transcription program during glucose deprivation makes it a promising candidate for inducing cell death in glucose-deprived tumor cells. Further research is needed to explore its potential applications in cancer treatment.
Originator
Silubin,Protochemie,Switz.
Manufacturing Process
105.6 g of n-butylamine hydrochloride and 79.3 g of dicyandiamide were
ground intimately and mixed. The mixture was heated by means of an oil
bath, gradually with stirring, and after thirty minutes when the internal
temperature had reached 150°C, an exothermic reaction ensued with internal
pressure rising to 178°C. The reaction mixture was removed from the oil bath
until the internal temperature had fallen to 150°C and then heating was
resumed at 150°C for one hour. The cooled fusion mixture was dissolved in 3
liters of acetonitrile and on cooling n-butyl-biguanide hydrochloride precipitated.
Therapeutic Function
Antidiabetic
Check Digit Verification of cas no
The CAS Registry Mumber 1190-53-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,9 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1190-53:
(6*1)+(5*1)+(4*9)+(3*0)+(2*5)+(1*3)=60
60 % 10 = 0
So 1190-53-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H15N5.ClH/c1-2-3-4-10-6(9)11-5(7)8;/h2-4H2,1H3,(H6,7,8,9,10,11);1H
1190-53-0Relevant articles and documents
Oral formulation comprising biguanide and an organic acid
-
, (2008/06/13)
An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness.
